每周股票复盘：心脉医疗（688016）获聚乙烯醇栓塞微球注册证

Core Viewpoint - The company, Xinmai Medical, has seen a stock price increase of 3.1% this week, closing at 97.98 yuan, with a total market capitalization of 12.077 billion yuan, ranking 27th in the medical device sector and 1716th in the A-share market [1] Company Announcements - Xinmai Medical's wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate for polyvinyl alcohol embolization microspheres, intended for the treatment of hypervascular solid organ malignant tumors [1] - This product marks the company's first embolization product in the field of tumor interventional therapy, with the registration certificate valid from January 28, 2026, to January 27, 2031 [1] - The company has multiple other tumor interventional products that have been approved or are under research, but actual sales will depend on market promotion efforts, making future revenue impact unpredictable [1]